CBX5 and non-small cell lung carcinoma: Targeting G9a significantly inhibited in vitro and in vivo growth and Wnt signaling pathways partially through down-regulating HP1α and epigenetically restoring APC2, via promoter demethylation, which finally suppressed NSCLC progression (Fig. 7).